WHEN PROFIT SHAPES CARE
Updated: Sep 2
What Documented Healthcare Failures Teach Us About Prevention, Transparency, Informed Choice, and Human Capacity
A World Serious™ | Human Capacity System | August 2026
The problem is not that healthcare makes money. The problem begins when the money changes the care. |
Modern medicine can stop an infection, repair a damaged joint, treat a dangerous disease, relieve suffering, and save a life. That truth deserves respect. So does another truth: healthcare operates inside commercial systems. Those systems reward certain actions, discourage others, and sometimes create conditions in which sales, market share, favorable evidence, or long-term revenue compete with prevention, transparency, and patient safety.
A World Serious™ does not ask people to distrust every doctor, reject every medication, or substitute internet opinion for trained clinical judgment. We ask something more demanding. We ask people to understand that trust is strongest when it is informed, evidence is strongest when its limitations are visible, and care is strongest when the person receiving it remains an active participant rather than a passive product moving through a system.
Blind trust is not a health strategy. Neither is blind rejection. |
THE AWS POSITION
A World Serious™ respects the dedication of physicians, nurses, pharmacists, therapists, technicians, emergency workers, researchers, and caregivers who serve people every day. Many work inside systems they did not design, under time, financial, regulatory, and administrative pressures they cannot individually control.
Our concern is not the existence of medicine or profit. Innovation must be funded. Expertise should be compensated. Organizations need sufficient revenue to recruit skilled people, maintain safe facilities, and develop better treatments. The concern is what happens when a financial incentive becomes powerful enough to distort the evidence, widen a market, delay a warning, reward unnecessary volume, or make continued dependence more profitable than durable health.
AWS therefore takes a clear position: people deserve truthful evidence, meaningful informed consent, appropriate medical care, preventive support, and the practical capacity to participate intelligently in decisions affecting their bodies and lives.
WHY THIS IS A HUMAN CAPACITY ISSUE
Health capacity is more than having access to a clinic or possessing health information. It is the developed ability to notice a problem, describe it accurately, ask better questions, evaluate benefits and risks, understand alternatives, follow through responsibly, monitor results, and build the daily conditions that support function over time.
When a person becomes only a diagnosis, a prescription, a procedure, or a billing code, that capacity can be pushed aside. Care becomes fragmented. One professional treats one symptom, another manages a side effect, and the person is left to connect the pieces. The more complicated the system becomes, the more capacity the individual and family need.
This is not theoretical. The World Health Organization reports that roughly one in ten patients is harmed in healthcare, that more than half of patient harm is preventable, and that medication-related harm accounts for a substantial portion of avoidable harm. A major United States analysis estimated that diagnostic errors contribute annually to approximately 371,000 deaths and 424,000 permanent disabilities across care settings. These numbers do not prove that profit caused every harm. They prove that passive trust is not enough.
GROUNDING FACTS
Patient harm usually reflects interacting system, organizational, technological, human, and patient factors. Economic and financial pressure is one recognized part of that larger system. Patient engagement, shared decision-making, clearer communication, and safer processes are therefore not attacks on medicine. They are established parts of patient safety.
GROUNDING EVIDENCE BASE
WHY FINANCIAL INCENTIVES REQUIRE SCRUTINY
A conflict of interest is not automatic proof of corruption. Industry funding can support valuable research, accelerate discovery, and help move useful treatments into practice. But a financial relationship is still relevant information because incentives can influence what is studied, how results are framed, what is promoted, and which risks receive attention.
A Cochrane review covering 75 papers found that industry-sponsored drug and device studies more often reported efficacy results and overall conclusions favorable to the sponsor's products than studies sponsored by other sources. HHS created the Open Payments system because relationships among manufacturers, physicians, and teaching hospitals may advance research while also creating the potential to influence clinical decision-making. Transparency does not settle the question. It makes the question possible.
GROUNDING FACTS
The evidence supports scrutiny, not blanket accusation. Funding source, payment relationships, study design, comparator choice, outcome selection, publication history, and the difference between absolute and relative benefit all matter when evaluating a health claim.
GROUNDING EVIDENCE BASE
DOCUMENTED CASES: WHEN THE INCENTIVE CHANGED THE CARE
The following cases are not internet rumors, political talking points, or broad accusations. They are grounded in guilty pleas, sentencing records, federal settlements, regulatory reviews, and a bipartisan congressional investigation. Civil allegations are identified as allegations. Criminal admissions are identified as admissions. That distinction matters.
1. PURDUE PHARMA AND OXYCONTIN
Purdue Pharma is the clearest warning against assuming that a regulated prescription is protected from aggressive commercial distortion. In 2020, Purdue admitted that it conspired to defraud the United States by impeding the Drug Enforcement Administration. According to the Department of Justice, Purdue represented that it maintained an effective anti-diversion program while continuing to market opioid products to more than 100 providers the company had good reason to believe were diverting opioids. Purdue also admitted to kickback arrangements intended to increase prescribing.
In April 2026, a federal court sentenced Purdue and ordered more than $5 billion in criminal penalties. The legal record does not require AWS to speculate about motive. The admissions and sentence establish that commercial activity, unlawful promotion, deception, and failures to protect the public operated inside a legitimate medical marketplace.
GROUNDING FACTS
Purdue's conduct demonstrates that professional prescribing, regulatory oversight, and legal availability do not eliminate the need for independent safety systems. When revenue grows through prescribing volume, safeguards against diversion, dependency, and harm must be stronger than the sales machinery surrounding the product.
GROUNDING EVIDENCE BASE
2. VIOXX: APPROVAL WAS NOT THE END OF THE SAFETY QUESTION
Vioxx, a prescription anti-inflammatory drug, was withdrawn from the United States market in September 2004 after a long-term controlled trial identified an increased risk of serious cardiovascular events compared with placebo. The FDA's later review treated the cardiovascular signal as a serious safety problem and emphasized the need for transparent reconsideration before any return to market.
In 2011, Merck agreed to pay $950 million to resolve criminal charges and civil claims connected to Vioxx promotion. Merck agreed to plead guilty to misdemeanor misbranding for promoting an unapproved use. The civil settlement resolved allegations that company representatives made inaccurate, unsupported, or misleading statements about cardiovascular safety to increase sales. The criminal plea and the civil allegations are not the same legal finding, but together they show why promotional claims and safety communication require independent scrutiny.
GROUNDING FACTS
Approval means that a product met the regulatory standard based on the evidence available for specified uses at a particular time. It does not make future evidence irrelevant. Post-market surveillance, accurate risk communication, and willingness to change course are essential parts of safe care.
GROUNDING EVIDENCE BASE
3. GSK, PAXIL, AND AVANDIA: WHEN THE EVIDENCE REACHING DOCTORS IS INCOMPLETE
In 2012, GlaxoSmithKline agreed to plead guilty and pay $3 billion to resolve criminal and civil liability involving unlawful promotion, failure to report safety data, and alleged false price reporting. The criminal information included misbranding Paxil and Wellbutrin and failing to report certain Avandia safety data to the FDA.
The Department of Justice stated that GSK promoted Paxil for depression in patients under 18 even though it was not FDA-approved for pediatric use. The government alleged that GSK helped distribute a misleading journal article that portrayed a trial as demonstrating efficacy, while two other studies that failed to demonstrate efficacy were not made available. GSK also agreed to plead guilty to failing to report certain Avandia cardiovascular safety data required by the FDA.
GROUNDING FACTS
Informed consent depends on the quality and completeness of the information reaching both clinician and patient. If unfavorable findings are withheld, minimized, or outpaced by promotion, the clinical encounter may appear informed while resting on an incomplete evidence base.
GROUNDING EVIDENCE BASE
4. PFIZER AND BEXTRA: WHEN MARKET EXPANSION CROSSES THE SAFETY BOUNDARY
In 2009, Pfizer and its subsidiary agreed to pay $2.3 billion to resolve criminal and civil liability involving pharmaceutical marketing. Pharmacia & Upjohn agreed to plead guilty to felony misbranding of Bextra with intent to defraud or mislead. The Department of Justice stated that Pfizer promoted Bextra for uses and dosages that the FDA had specifically declined to approve because of safety concerns.
The FDA had concluded that Bextra's overall benefit-risk profile was unfavorable and recommended withdrawal from the United States market, citing cardiovascular risks, serious skin reactions, and a lack of demonstrated therapeutic advantage sufficient to offset those concerns. This was not merely a disagreement over marketing language. The commercial expansion pushed toward uses and doses the regulator had rejected on safety grounds.
GROUNDING FACTS
Off-label prescribing by a clinician and unlawful off-label promotion by a manufacturer are not the same act. Clinicians may lawfully use professional judgment within applicable standards. Manufacturers are restricted from marketing unapproved uses. Patients benefit when that distinction is understood and when promotional pressure does not masquerade as independent medical judgment.
GROUNDING EVIDENCE BASE
5. INSULIN PRICING: WHEN EVERY PART OF THE CHAIN CAN BENEFIT FROM A HIGHER NUMBER
Insulin shows that a profit-first problem does not always look like hidden safety data or illegal promotion. Sometimes it is built into pricing architecture. A bipartisan Senate Finance Committee investigation reviewed more than 100,000 pages of internal documents, memoranda, and rebate agreements from major insulin manufacturers and pharmacy benefit managers.
The Committee reported that manufacturers aggressively raised list prices without significant advances in efficacy, sometimes increasing prices in lockstep. It also found that pharmacy benefit managers used formulary leverage to obtain larger rebates and fees, while some administrative fees rose with the list price. The result was a structure in which several participants could benefit from a higher list price while patients exposed to deductibles or coinsurance could pay more at the pharmacy counter.
GROUNDING FACTS
A healthcare market can produce essential treatment and still contain incentives that work against affordability. The capacity question is not whether insulin is necessary. For many people it is life-sustaining. The question is whether the pricing system serves the person whose life depends on it.
GROUNDING EVIDENCE BASE
THE PATTERN IS BIGGER THAN ANY ONE COMPANY
These cases differ in facts, time period, product, and legal outcome. They should not be flattened into one accusation. Yet a common pattern is visible. Commercial systems repeatedly become dangerous when the organization earning the revenue controls too much of the information, the promotion, the professional influence, or the pathway through which the patient must move.
The distortion can enter through market expansion, selective evidence, incomplete safety reporting, pricing arrangements, sales incentives, paid influence, or regulatory delay. It does not require every participant to be dishonest. A system can produce a harmful direction when ordinary people respond rationally to incentives that reward the wrong outcome.
That is why blaming individual clinicians is not enough. It is also why telling patients to simply do their own research is not enough. Safe care requires better systems, honest evidence, professional accountability, transparent financial relationships, and people who have enough capacity to ask questions without pretending they have replaced clinical expertise.
THE FALSE CHOICE: OBEY EVERYTHING OR REJECT EVERYTHING
Public frustration often swings between two weak positions. The first says that an approved treatment, professional title, institutional recommendation, or official guideline should end the conversation. The second says that because institutions have failed, professional medicine should be rejected altogether.
Both positions surrender judgment. Blind compliance gives away authority. Blanket rejection abandons evidence, expertise, and treatments that may be necessary. Capacity lives in the harder middle: respect expertise, verify consequential claims, understand uncertainty, ask who benefits, recognize what remains unknown, and make decisions proportionate to the stakes.
The answer to institutional failure is not institutional worship or institutional rejection. It is stronger human capacity. |
THE HEALTH CAPACITY PROTECTION STANDARD
The following standard is not a substitute for clinical care. It is a practical framework for participating in care more responsibly, especially when a treatment is long-term, high-risk, expensive, difficult to reverse, or being considered for a child or vulnerable adult.
1. Name the actual problem. Ask what condition, symptom, risk, or functional limitation is being addressed. A vague problem invites a vague solution.
2. Clarify the purpose of the treatment. Is the goal to cure, prevent, stabilize, reduce symptoms, improve function, or buy time? A treatment can be appropriate without accomplishing every one of those goals.
3. Ask for the benefit in understandable terms. Request the likely benefit, the size of the benefit, how quickly it may appear, and how success will be measured. Relative improvement can sound larger than absolute improvement.
4. Ask what can go wrong. Discuss common side effects, serious risks, interactions, withdrawal or discontinuation concerns, and the signs that require immediate attention.
5. Understand the alternatives. Ask about other treatments, watchful waiting when appropriate, rehabilitation, behavioral or environmental support, and what is likely to happen without the proposed intervention.
6. Review the whole picture. Maintain an accurate list of prescriptions, over-the-counter products, supplements, allergies, diagnoses, and prior reactions. Fragmented care becomes more dangerous when no one can see the full load.
7. Check the evidence and the source. Ask whether the recommendation rests on randomized trials, observational evidence, professional consensus, regulatory judgment, or emerging practice. Look for funding relationships and important evidence gaps.
8. Use a second opinion when the stakes justify it. A second qualified opinion is especially valuable before an irreversible procedure, a lifelong treatment commitment, or a decision made under intense pressure.
9. Build the conditions that treatment cannot replace. Sleep, nutritious food, movement, recovery time, relationships, stress regulation, environmental safety, and daily structure do not solve every disease. They still shape resilience, function, and recovery.
10. Monitor, document, and reassess. Record symptoms, function, side effects, questions, and changes. Know when the plan will be reviewed. Do not abruptly stop or change prescribed treatment without appropriate clinical guidance.
WHAT AWS BUILDS
A World Serious™ works in the human-capacity lane. We help people slow down a complicated problem, identify what is known and unknown, organize daily conditions, strengthen follow-through, prepare better questions, and take greater responsibility for the parts of life they can influence.
FARMACY ProVisions™ is a Human Life Capacity system built from practical provisions, daily practices, and natural conditions that support sustainable health and function. Its operating principle is simple: it is rarely one thing. Health and dysfunction usually emerge from a composition of conditions.
That principle does not eliminate medicine. It places medicine inside a larger life. A prescription may be necessary, but it cannot sleep for you, move your body, repair a relationship, prepare your food, manage your environment, tell the complete truth about your habits, or build the structure required for recovery. A procedure can repair tissue, but it cannot build the daily capacity that protects the result.
AWS does not diagnose disease or direct individual treatment. Clinical diagnosis, prescribing, and medical procedures belong with appropriately licensed professionals. Our responsibility is to help people arrive at those encounters better prepared, remain engaged through them, and build the conditions around care that support sustainable function.
CONCLUSION: HEALTH BEFORE PROFIT
The documented record is strong enough. Purdue admitted fraud and kickback conspiracies. Merck resolved criminal charges and civil allegations involving Vioxx promotion and cardiovascular safety statements. GSK agreed to plead guilty in a case involving misbranding and failure to report safety data. Pfizer's subsidiary agreed to plead guilty to felony misbranding of Bextra. A bipartisan Senate investigation found pricing incentives that rewarded higher insulin list prices across the supply chain.
These cases do not prove that every company is corrupt, every treatment is unnecessary, or every professional relationship is compromised. They prove something more useful: the healthcare label does not remove ordinary human incentives, institutional pressure, or commercial risk.
Healthcare should build health, relieve suffering, restore function, and protect life. When treatment is necessary, it should be supported by honest evidence and meaningful consent. When prevention is possible, it should not be neglected because another intervention is easier to bill. When uncertainty remains, it should be disclosed rather than marketed away. When financial interests exist, they should be visible.
A person should never be expected to navigate this alone, but neither should a person be trained into permanent passivity. The responsible path is informed partnership: competent professionals, transparent systems, better evidence, and stronger human capacity.
Health before profit. Evidence before promotion. Capacity before dependence. |
EDUCATIONAL SCOPE
This Capacity Report provides general educational information. It does not diagnose, prescribe, or replace individualized medical care. Decisions about starting, stopping, or changing prescribed treatment should be made with appropriately qualified clinicians. Urgent or potentially life-threatening symptoms require appropriate emergency care.
Comments